Douglas A Donahue
Douglas Donahue (Doug) obtained his MS in Biological Sciences from Bowling Green State University in 2004 with emphasis on general toxicology, endocrinology, and environmental pollutants. He holds both DABT and ERT certifications.
He currently serves as the Head of Preclinical Toxicology for GSK Vaccines, supporting key mRNA-based vaccines.
For the past 18 years, Doug’s career has focused on practical applications for industrial, cosmetic, device, pharma and vaccine product development. Positions held at GSK, WIL Research, KAO, Covance, and Becton-Dickenson have allowed Doug to shepherd more than 300 successful global product registrations/approvals with major Regulatory agencies including REACh, TSCA, EPA, FDA and EMA. Significant areas of expertise include DART, medical device registrations, and rare disease treatments.
Although he has worked primarily in an industry setting, Doug actively contributes to the academic community through peer-reviewed journal publications and serves as a guest lecturer for University of Texas Medical Branch at Galveston. He is also grant reviewer for Alternatives Research & Development Foundation (ARDF), which supports novel, viable strategies to in-vivo animal testing.
Doug mentored many early-career toxicologists at Covance, Becton-Dickinson and now at GSK; helping train the next generation of toxicology professionals. Doug also formally participates in the ACT Mentorship program meeting with his Mentee on a quarterly basis.
Doug is an active member of ACT (since 2008) serving as an elected member of the ACT Membership committee (2020-2023) and an appointed member of the ACT Program Committee (2018-2020), co-chairing sessions and continuing education courses. He remains a full member of the Society of Toxicology (SOT) and the British Toxicology Society (BTS).